Therma Bright's Venowave VW5 Secures Medicare Reimbursement Amid Growing Compression Therapy Market

Therma Bright Inc. has achieved a significant milestone in the compression therapy market with its Venowave V5 medical compression pump receiving a permanent Healthcare Common Procedure Coding System code from the U.S. Centers for Medicare and Medicaid Services. This designation makes the Venowave VW5 the only Medicare-approved, reimbursable mobile mechanical compression system available in the United States, positioning the company for substantial market growth. The FDA-designated Durable Medical Equipment device provides patients with a lightweight and compact solution for managing post-operative recovery, pain, and swelling through simple and comfortable treatment options.

The company's market expansion has been accelerated through strategic distribution partnerships with major medical device distributors. DME Authority, a national distributor, has committed to a substantial inventory purchase including an initial order of 1,750 Venowave VW5 units, representing potential HCPCS code reimbursements of approximately $1.43 million. Another national distributor, Valor Medical, has placed an initial order for 100 units with expectations for regular future purchases. These distribution agreements significantly enhance Therma Bright's market penetration and revenue potential in the growing compression therapy sector.

The global compression therapy market presents substantial growth opportunities for medical technology companies. According to Straits Research, the market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033, representing a compound annual growth rate of 7.30%. This growth trajectory reflects increasing demand for innovative medical devices that address post-operative care and chronic condition management. The permanent Medicare reimbursement status provides Therma Bright with a competitive advantage in capturing market share within this expanding industry segment.

Beyond the Venowave VW5, Therma Bright is developing additional medical technologies that complement its compression therapy offerings. The company is pursuing FDA classification for its acoustic AI Digital Cough Technology, a remote therapeutic monitoring solution designed to help healthcare providers and epidemiologists collect and analyze respiratory data. This technology represents the company's expansion into digital health monitoring and positions Therma Bright as an emerging player in the broader medical device technology sector with potential for continued innovation across multiple therapeutic areas.